heparin / Ockham Biotech - LARVOL DELTA

What Are Breast Hematomas? (Verywell Health) - "A breast hematoma can happen to anyone regardless of age or menopausal status. It may be caused by trauma, or procedures like a breast biopsy or breast surgery.1 Breast hematomas are usually visible on a mammogram, and can sometimes look like breast cancer on other imaging as well. Treatment usually consists of waiting for the hematoma to go away over time, but surgery may sometimes be needed."

Online posting

Review: Why Are Blood Clots Such a Major Problem in Severe COVID-19? (Science) - "In the early days of the New York COVID-19 outbreak, as March turned to April, haematologist Jeffrey Laurence was called to consult on the case of a 32-year-old bodybuilder. Nurses had noticed an odd rash on his buttocks, 'as if you had kind of peeled away the skin layer and were seeing what blood vessels look like on his bottom,' recalls Laurence..."

Media quote

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus (TCTMD) - "'We always increase the dose in obese patients,' said Susen. 'In our ARDS patients, and in patients in which a diagnosis [of PE] is more than expected, we give a therapeutic dose of heparin. We don't wait for the CTPA because in a short time frame, the patient can become more severe and you can't always confirm with CTPA.'"

Media quote

Reader Responses: How would you treat these patients with acute stroke who are positive for lupus anticoagulant or aCL antibodies? (ASH Clinical News) - "If the stroke is very large, then I would be hesitant to start anticoagulation. I would ask the neurologist what the risk is for postinfarction bleeding. If the risk is low, then I would not hesitate to start anticoagulation....Bassam Matar, MD."

Media quote

Subtherapeutic heparin: As stories multiply, concerns mount (TCTMD) - "As of now, the American College of Cardiology (ACC) has no specific plan to acknowledge or address any issue with heparin...Richard Kovacs, MD...told TCTMD. However, he said 'we have long supported the FDA's efforts at monitoring the safety of the drug supply....Everybody who takes care of patients should realize that it is all of our responsibilities to maintain the safety of the drug supply, and so observing an aberration in how a patient responds to a drug is important, and it is our duty to report those through MedWatch.'"

Media quote

Description of Anti-Xa Monitoring Practices During Low Molecular Weight Heparin Use (ACFORUM 2019) - P=NA, N=224; "Given that the majority of anti-Xa levels were therapeutic, anti-Xa monitoring may not be needed even in high-risk patient populations. Further research is still needed to explore a connection between anti-Xa monitoring and clinical outcomes."

Clinical data